Moderna Up 70% After 9-0 FDA Vote, But Wall Street Averages Predict 44% Decline

💡 Moderna's stock price has surged 70% in a month, but analysts predict a decline of 44%.

The pharmaceutical company Moderna has seen its stock price surge by over 70% in the last month, following a unanimous 9-0 FDA vote to approve its COVID-19 vaccine for children under 6 years old. This news has sent shockwaves through the market, with many investors taking a bullish stance on the company's future prospects.

Market Reactions

The rapid rise in Moderna's stock price has led to a flurry of activity in the market, with many analysts revising their price targets upwards. However, not everyone is convinced that Moderna's stock will continue to rise. Wall Street's average price target for the company stands at $44% below its current price, suggesting that investors may be in for a correction.

Analyst Predictions

While some analysts are predicting a continued rise in Moderna's stock price, others are warning of a potential bubble burst. The company's high valuation multiple and debt-to-equity ratio have some investors concerned that the stock is due for a sharp decline.

What It Means for Investors